Drug profile · INN
febuxostat
ADENURIC
febuxostat (ADENURIC) is a xanthine dehydrogenase inhibitor. Associated with A.Menarini Australia Pty Limited. Route of administration: oral. Current US regulatory status: approved.
Drug details — febuxostat
- US status
- approved
- Class
- Musculo-skeletal system (M04)
- Route
- ORAL
- Patents
- 5
- Programs
- 16
- Data quality
- 0.89
Quick answer
febuxostat (ADENURIC) is a xanthine dehydrogenase inhibitor. Associated with A.Menarini Australia Pty Limited. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Xanthine dehydrogenase inhibitor
Primary target: Xanthine dehydrogenase/oxidase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 9107912
Methods for concomitant treatment of theophylline and febuxostat
granted -
US 8742129
Crystalline forms of febuxostat
granted -
US 8609856
Crystalline forms of Febuxostat
granted -
US 8415481
Crystalline form of febuxostat
granted -
US 8372872
Methods for concomitant treatment of theophylline and febuxostat
granted
Frequently asked questions
What is febuxostat?
febuxostat (ADENURIC) is a xanthine dehydrogenase inhibitor. Associated with A.Menarini Australia Pty Limited. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for febuxostat?
ADENURIC is a marketed brand name for febuxostat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of febuxostat?
febuxostat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.